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Summary: This manuscript takes a fresh look at group sequential methods applied to two-sample tests of censored
survival data and proposes an alternative method of defining and evaluating treatment benefit. Our method re-
purposes traditional censored event time data into a sequence of short-term outcomes taken from (potentially
overlapping) follow-up windows. A new two-sample restricted means test based on this restructured follow-up data is
proposed along with group sequential methods for its use in the clinical trial setting. This method compares favorably
with existing methods for group sequential monitoring of time-to-event outcomes, including methods for monitoring
the restricted means test and the logrank test. Our method performs particularly well in cases where there is a delayed
treatment effect and/or a subset of cured patients. As part of developing group sequential methods for these analyses,
we consider asymmetric error spending approaches that differentially limit the chances of stopping incorrectly for
perceived efficacy versus perceived harm attributed to the investigational arm of the trial. Recommendations for how
to choose proper group sequential stopping boundaries are given, with supporting simulations and an example from
the AIDS Clinical Trial Group.
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Nonparametric Group Sequential Methods for Evaluating Survival Benefit 1
1. Introduction
Traditionally in the censored time-to-event setting, with or without group sequential mon-
itoring, two-sample treatment comparisons are based on restricted mean event times or
integrated weighted hazard differences estimated over many follow-up years (Mantel, 1963;
Gehan, 1965; Mantel, 1966; Breslow, 1970; Peto and Peto, 1972; Prentice, 1978; Harrington
and Fleming, 1982; Tsiatis, 1982; Pepe and Fleming, 1989; Li, 1999; Murray and Tsiatis,
1999). Investigators and biostatisticians alike hope that treatment differences will emerge
throughout the trial, anticipating Kaplan-Meier curves that snake farther and farther apart
as the end of follow-up draws near.
In this manuscript we embrace the philosophy that for each patient in a clinical trial,
short-term survival over repeated, overlapping intervals are observed, and that each of these
has value in assessing treatment benefit. In short, time-to-event data can be reformulated
as repeated short-term longitudinal outcomes subject to censoring, and then analyzed using
methodology that takes into account both the censored nature of the data as well as the
correlation between short-term events measured from the same individual.
Tayob and Murray (2016) followed this train of thought when they evaluated the behavior
of an overall τ -restricted mean estimated from multiple, overlapping τ -length follow-up
windows. Their overall estimated τ -restricted mean integrates area under an estimated
survival curve, but instead of using time-to-event data in its original form, Tayob and
Murray estimate the curve from a massive censored longitudinal repeated measures dataset
with multiple overlapping short-term outcomes taken from each individual’s observed follow-
up. Corresponding confidence intervals nonparametrically take into account the correlation
between outcomes taken from the same individual. The choice of τ is typically taken from
the context in which the method is applied. For instance, in pulmonary literature a 1-year
restricted mean is common, and fairly stable over time as seen in Tayob and Murray. In
scenarios where τ -restricted means are not stable over time, the overall τ -restricted mean
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is an estimate from a mixture distribution that results from combining information from
overlapping follow-up windows.
In this manuscript we propose a new two-sample test comparing τ -year restricted means
estimated in the manner proposed by Tayob and Murray. As with existing two-sample
tests, this test is valid under the null hypothesis of no treatment difference regardless of
the distributions under study. We also develop group sequential methods for monitoring a
clinical trial via the proposed statistic, along with graphics displaying the estimated overall
years of life gained per τ time units when assigned the superior treatment.
Group sequential monitoring via nonparametric two-sample tests has a long and respected
history in clinical trial design. Classic group sequential analysis literature gives stopping rules
for statistically significant treatment benefit or harm (Pocock, 1977; O’Brien and Fleming,
1979). The most common approach for controlling type I error throughout a trial is to
use error spending functions proposed by Lan and DeMets (1983), which allow for both
symmetric and asymmetric stopping rules. Symmetric stopping rules imply that stopping
early for statistically significant treatment differences have the same cost, whether benefit
or harm is attributed to the experimental therapy. Asymmetric bounds are useful when
consequences of stopping early are different according to the treatment difference that is
emerging (Tsiatis, 1981; DeMets and Ware, 1982). Futility bounds have become increasingly
popular as a mechanism for stopping a trial that is unlikely to end in a new treatment
recommendation (Friedman et al., 2015; Harrington, 2012). These types of bounds also
avoid the ethically uncomfortable scenario of trial termination only after statistical proof
of increased mortality from the new treatment.
Our manuscript proceeds with a description of notation in Section 2. In Section 3 we
describe the proposed test statistic in the case where a single analysis is performed, with
an extension to the group sequential setting given in Section 4; Derivations behind methods
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in Sections 3 and 4 are relegated to Supplementary Materials. In Section 4, we also review
symmetric versus asymmetric stopping boundaries, with a modified recommendation for
safety monitoring. Section 5 summarizes finite sampling behavior of our group sequential
monitoring procedure in a variety of clinical trial settings. An example from the AIDS Clinical
Trial Group is given in Section 6 and followed by discussion in Section 7.
2. Notation
Our ultimate goal is to group sequentially monitor two-sample tests that compare estimates
of τ -restricted mean lifetimes, µg(s, τ), g = 1, 2, incorporating information from multiple,
potentially overlapping, short-term follow-up windows of length τ . For simplicity, we first
describe notation for the one-sample case, submerging the g subscript.
2.1 Description of Random Variables
Suppose i = 1, . . . , N patients participate in a clinical trial. Patient-specific random variables
are measured against two different time scales in the group sequential setting: calendar time,
s, and study time, t. Study time, t, indexes time from a patient’s clinical trial entry; length
of life, length of follow-up and other clinical trial endpoints are described on this time-scale.
Calendar time, s, indexes time from the initiation of the overall study; patient entry times
and interim analysis times are described on this time scale.
In particular, study time indexed random variables include failure times, Ti and potential
loss-to-follow-up times Vi, i = 1, . . . , N . On the calendar time scale, we define random
study entry times, Ei, for participant i = 1, . . . , N, as well as interim analysis times,
s = s1, s2, . . ., which are (non-random) study design parameters. At interim analysis time
s, n(s) =
∑N
i=1 I(Ei 6 s) individuals have entered the trial with n(s) = N for s >
max(E1, . . . , EN). An individual’s maximum follow-up time at analysis time s is admin-
istratively capped at s−Ei. Hence, the censoring random variable, Ci(s) = min(Vi, s−Ei),
for individual i can potentially change at each analysis time s, depending on the censoring
mechanism. We assume that Ti is independent of Ci(s), i = 1, . . . , N . For patients who have
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entered the trial, observed event times at analysis time s are Xi(s) = min {Ti, Ci(s)}, with
corresponding failure indicator variables δi(s) = I{Ti 6 Ci(s)}, i = 1, . . . , n(s).
Notation for residual lifetime random variables are needed to define short-term outcomes
during several, potentially overlapping, τ -length follow-up windows of interest. The starting
times of these follow-up windows, t ∈ {t1, t2, . . . , tb}, are non-random design parameters
measured on the study time scale with t1 = 0, and b indicating the total number of windows.
We define the residual lifetime from study time t observed at analysis time s as Xi(s, t) =
(Xi(s)− t)I{Xi(s) > t} with corresponding failure indicator δi(s, t) = δi(s)I{Xi(s) > t}. A
third time-scale metric, window time u, indexes time from the beginning of each follow-up
window. We use the window time metric as a common time-scale for residual lifetime random
variables, Xi(s, t1), Xi(s, t2), . . . Xi(s, tb).
Figure 1 displays data for 3 example individuals, with random variables specific to subject
A given in detail. Patient entry times EA, EB, EC and interim analysis times s1, s2 are given
on the calendar time scale. Death, loss to follow-up, administrative censoring and window
start times are given on the study time scale. At the second interim analysis conducted
on January 1, 2016, n(s2) = 3 individuals have entered the study. Subject A contributes
information from three windows starting at t1 = 0, t2 = 6 months and t3 = 12 months.
Observed residual lifetime and censoring indicator data pairs contributed by Subject A at the
second analysis time are (17, 1), (11, 1) and (5, 1). In terms of short-term follow-up windows
of length τ = 12 months, Subject A contributes uncensored information from three windows:
in the first window, Subject A lives 12 of 12 months, in the second Subject A lives 11 of
12 months, and in the third window Subject A lives 5 of 12 months. Any test statistic
incorporating multiple short-term outcomes taken from an individual as laid out in Figure
1 will need to account for potential correlation between these outcomes.
[Figure 1 about here.]
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2.2 Counting Process Notation and Estimation
For an individual i who has entered the trial by interim analysis time s, Ni(s, t, u) =
I{Xi(s, t) 6 u, δi(s, t) = 1} and Yi(s, t, u) = I{Xi(s, t) > u} are the counting and at
risk processes for the number of events occurring no later than window time u within the
follow-up window starting at study time t. From Figure 1, consider Subject A’s data at
the 2nd interim analysis time, s2, from the follow-up window starting at t2 = 6 months.
Subject A’s corresponding counting process data at window times u = 11−, 11, and 11+
months are {NA(s2, t2, 11−) = 0, YA(s2, t2, 11−) = 1}, {NA(s2, t2, 11) = 1, YA(s2, t2, 11) = 1}
and {NA(s2, t2, 11+) = 1, YA(s2, t2, 11+) = 0}.
LetN(s, t, u) =
∑n(s)
i=1 Ni(s, t, u) and Y (s, t, u) =
∑n(s)
i=1 Yi(s, t, u) represent processes summed
across individuals entered by interim analysis time s. For individual i at interim analysis
s, let Ni(s, u) =
∑b
j=1Ni(s, tj, u) count the observed residual lifetime events across the b
follow-up windows attributed to individual i that are seen prior to window time u; the
corresponding at risk process is Yi(s, u) =
∑b
j=1 Yi(s, tj, u). Ni(s, u) has the potential to
count the same event more than once, since this event may be contained in more than one
follow-up window. Likewise, Yi(s, u), includes at-risk processes from the same individual
more than once from follow-up windows that overlap. Combining all information available at
interim analysis time s regarding event and at-risk information for window time u we define
N(s, u) =
∑n(s)
i=1 Ni(s, u) and Y (s, u) =
∑n(s)
i=1 Yi(s, u).
At analysis time s, let hazard function λ(s, t, u) = lim∆u→0[Pr{u 6 Xi(s, t) 6 u +
∆u, δi(s, t) = 1|Xi(s, t) > u}/∆u] and
λW (s, u) =
∑b
j=1 λ(s, tj, u)Pr{Xi(s, tj) > u}∑b
l=1 Pr{Xi(s, tl) > u}
.
As in standard group sequential methods, we assume that analysis time does not affect the
true event-time hazard, so that the superfluous s notation in λ(s, t, u) can be dropped to
become λ(t, u). However, because λW (s, u) corresponds to a mixture distribution of residual
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lifetimes contributed from individuals at time s, and is a function of Pr{Xi(s, t) > u} that
depends on follow-up, analysis time s can influence this term.
3. Two-sample test at a single analysis time, s
In this section, we propose a two-sample test that compares average lifetime per τ follow-up
years. The test is inspired by overall τ -restricted mean estimates developed by Tayob and
Murray (2016) that incorporate information from repeated, overlapping follow-up windows
of length τ , subject to censoring. Additional subscripts g, g = 1, 2, indicate treatment group
when used with notation from the last section; random variables from different treatment
groups are assumed independent. We assume a single analysis at calendar time s.
For treatment g at analysis time s, following results from Tayob and Murray,
µˆg(s, τ) =
∫ τ
0
exp
{
−
∫ u2
0
dNg(s, u1)
Yg(s, u1)
}
du2
consistently estimates µg(s, τ) =
∫ τ
0
exp
{− ∫ u2
0
λWg (s, u1)du1
}
du2, the average lifetime per
τ time units as measured from the mixture distribution of short-term, overlapping τ -length
follow-up windows starting at times t1, . . . , tb. Our proposed two-sample test becomes
T (s) =
√
n1(s)n2(s)
n1(s) + n2(s)
{µˆ1(s, τ)− µˆ2(s, τ)}.
Let pˆig(s) = ng(s)/{n1(s) + n2(s)}, g = 1, 2. As shown in Web Appendix A, under the null
hypothesis of µ1(s, τ) = µ2(s, τ), the asymptotic limiting distribution of T (s) has a mean 0
Normal distribution with variance that can be estimated by pˆi2(s)σˆ
2
1(s) + pˆi1(s)σˆ
2
2(s), where
σˆ2g(s) =
∑ng(s)
i=1 [zi{µˆg(s, τ)}−z¯{µˆg(s, τ)}]2/[ng(s)−1], with zi{µˆg(s, τ)} =
∑b
j=1 zij{µˆg(s, τ)};
z¯{µˆg(s, τ)} =
∑ng(s)
i=1 zi{µˆg(s, τ)}/ng(s) and
zij{µˆg(s, τ)} =
∫ τ
0
exp
{
−
∫ u2
0
dNg(s, u1)
Yg(s, u1)
}{∫ u2
0
dNgi(s, tj, u1)− Ygi(s, tj, u1)dNg(s,u1)Yg(s,u1)
Yg(s, u1)/ng(s)
}
du2
An approximate 1− α level confidence interval for the average difference in lifetime per τ
time units, µ1(s, τ)−µ2(s, τ), becomes {µˆ1(s, τ)−µˆ2(s, τ)}±Z1−α/2
√
σˆ21(s)/n1(s) + σˆ
2
2(s)/n2(s),
where Z1−α/2 is the 100×(1−α/2)% quantile of the standard Normal distribution. A standard
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Normal(0,1) version of the test statistic can be calculated using
T˜ (s) =
T (s)√
pˆi2(s)σˆ21(s) + pˆi1(s)σˆ
2
2(s)
=
√
n1(s)n2(s)
n2(s)σˆ21(s) + n1(s)σˆ
2
2(s)
{µˆ1(s, τ)− µˆ2(s, τ)}.
In describing efficiency of their estimation procedure, Tayob and Murray (2016) give
guidance on selection of follow-up window start times t1, t2, . . . , tb based on the special case
where event-times follow an exponential distribution. In this case, an analysis of their closed
form asymptotic variance showed that, for a fixed number b of incorporated windows, equal
spacing of t1, t2, . . . , tb gave the smallest possible variability. For any fixed duration follow-up
period, simulations also indicated increased efficiency in estimation with increasing b, even
though increases in b create increasing amounts of overlap between a patient’s incorporated
short-term follow-up windows. However, Tayob and Murray (2016) found that increasing
b beyond approximately (2s − τ)/τ gave diminishing returns in efficiency; they ultimately
recommended incorporating outcomes from follow-up windows starting after every τ
2
units
of follow-up time, i.e., t = {0, τ
2
, τ, . . . , s− τ}. For instance, with τ = 1 year and an interim
analysis 3 years into the trial, we would incorporate information from 1-year duration follow-
up windows starting at t1 = 0, t2 = 0.5 years, t3 = 1 year, t4 = 1.5 years and t5 = 2 years.
4. More Than One Analysis at Calendar Times, s1, . . . , sK
At analysis time s, a decision to continue or end the clinical trial is based on the standardized
test statistic, T˜ (s), exceeding predetermined lower or upper critical values (CVs), cL(s)
and cU(s), respectively. When K > 1 analyses are planned, group sequential methodology
tells us that CVs, {cL(s1), cU(s1)} , . . . , {cL(sK), cU(sK)} , corresponding to test statistics,
T˜K =
{
T˜ (s1), . . . , T˜ (sK)
}
, must be carefully chosen to preserve an overall type I error of
α (Pocock, 1977; O’Brien and Fleming, 1979; DeMets and Lan, 1994).
CVs, {cL(sk), cU(sk)} , for the kth analysis (k = 1, . . . , K) can be calculated from the
multivariate distribution of T˜k. As shown in Web Appendices A and B, T˜k has a mean zero
multivariate Normal distribution with k×k covariance matrix Σ, where the diagonal elements
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are equal to one and the off-diagonal elements, σk1k2 = σk2k1 , k1 < k2, can be estimated by
σˆk1k2 ={pˆi2(sk1)σ˜21(sk1) + pˆi1(sk1)σ˜22(sk1)}−
1
2{pˆi2(sk2)σˆ21(sk2) + pˆi1(sk2)σˆ22(sk2)}−
1
2
×
2∑
g=1
√
pˆi3−g(sk1)pˆi3−g(sk2)ψˆg(sk1 , sk2)
( ng(sk1 )∑
i=1
{ng(sk1)− 1}−1
× [z˜i{µˆg(sk1 , τ)} − ¯˜z{µˆg(sk1 , τ)}] [zi{µˆg(sk2 , τ)} − z¯{µˆg(sk2 , τ)}]
)
where pˆig, σˆ
2
g(sk2), zi{µˆg(sk2 , τ)} and z¯{µˆg(sk2 , τ)} have been defined in Section 3 with s = sk2
and ψˆg(sk1 , sk2) = ng(sk1)/ng(sk2). The zij{µˆg(sk1 , τ)} terms in σˆ2g(sk1), zi{µˆg(sk1 , τ)} and
z¯{µˆg(sk1 , τ)} are replaced with
z˜ij{µˆg(sk1 , τ)} =
∫ τ
0
exp{−
∫ u2
0
dNg(sk1 , u1)
Yg(sk1 , u1)
}
[∫ u2
0
b∑
l=1
ng(sk2 )∑
i=1
I{Tgi > u1 + tl}
ng(sk1 )∑
i′=1
I{Cgi′(sk1) > u1 + tl}

−1
× ng(sk1)ng(sk2)Ygi(sk1 , tj, u1)
{
dNgi(sk2 , tj, u1)
Ygi(sk2 , tj, u1)
− dNg(sk1 , u1)
Yg(sk1 , u1)
}]
du2
when calculating σ˜2g(sk1), z˜i{µˆg(sk1 , τ)} and ¯˜z{µˆg(sk1 , τ)}.
Examples of calculating CVs based on the joint distribution of T˜k are described further
in Sections 4.1 and 4.2. Section 4.1 reviews how to calculate CVs based on symmetric type
I error spending functions that are in common use. In Section 4.2 we describe calculation of
CVs based on asymmetric error spending approaches that differentially limit the chances of
stopping incorrectly for perceived efficacy versus harm attributed to the investigational arm.
4.1 Symmetric Spending Functions
Interim analysis CVs are often based on a monotonically increasing spending function,
α(γ), 0 6 γ 6 1, with α(0) = 0 and α(1) = α, the desired overall type I error. A valuable
advantage of spending functions is increased flexibility in scheduling interim analyses, for
instance as prespecified accrual and follow-up targets are met. Spending functions that
approximate the Pocock (P) and the O’Brien-Fleming (OF) approaches to type I error
control are αOF (γ) = 2 − 2Φ(Z1−α/2/√γ) and αP (γ) = α ln{1 + (e − 1)γ}, respectively.
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At interim analysis time s, γ is often taken to be the proportion of available statistical
information relative to the information anticipated at the final analysis. Another common
choice for γ is the proportion of expired calendar time relative to the planned trial duration.
As a simple example of the OF spending function with α = 0.05, suppose K = 2 analyses
are planned at s1 and s2. We choose to use symmetric bounds so that cL(s1) = −cU(s1)
and cL(s2) = −cU(s2). Further suppose that at s1, γ = 23 , giving αOF (23) = 0.016; at the
final analysis time γ = 1 and αOF (1) = 0.05 by design. Since under the null hypothesis
T˜ (s1) has an approximate Normal(0,1) distribution, and no type I error has been spent
prior to s1, {cL(s1), cU(s1)} =
{Z0.016/2,Z1−0.016/2} . Calculation of {cL(s2), cU(s2)} is not as
straightforward due to stochastic dependence between T˜ (s1) and T˜ (s2). The symmetric OF
spending function allows 0.05 − 0.016 = 0.034 type I error to be spent at the 2nd analysis,
with 0.017 error allocated towards incorrectly claiming a statistically significant treatment
benefit and 0.017 error towards incorrectly claiming statistically significant treatment harm.
Calculations for {cL(s2), cU(s2)} are only relevant when the trial continues beyond the first
interim analysis (Z0.016/2 < T˜ (s1) < Z1−0.016/2) and need to satisfy:
Pr
{
T˜ (s2) /∈ (cL(s2), cU(s2)) | Z0.016/2 < T˜ (s1) < Z1−0.016/2, H0
}
=
Pr
{
Z0.016/2 < T˜ (s1) < Z1−0.016/2, T˜ (s2) /∈ (cL(s2), cU(s2))|H0
}
Pr
{
Z0.016/2 < T˜ (s1) < Z1−0.016/2|H0
} = 0.034
1− 0.016 ≈ 0.035.
Suppose the estimated correlation between T˜ (s1) and T˜ (s2), i.e. σ12, is 0.5. Modern
software packages can easily generate a large number of mean zero bivariate normal iterates
with correlation 0.5, {Zm(s1), Zm(s2)} ,m = 1, . . . ,M ; in simulation we used M=10 million.
The desired CVs, cL(s2) = −cU(s2), satisfying Pr{T˜ (s2) /∈ (cL(s2), cU(s2)) | Z0.016/2 <
T˜ (s1) < Z1−0.016/2, H0} = 0.035 are calculated by first subsetting the iterates who failed
to reject at s1, i.e., the set S(s1) =
{
m ∈ 1, . . . ,M : Z0.016/2 < Zm(s1) < Z1−0.016/2
}
. Then
cU(s2) = −cL(s2) is the 1-0.035=0.965 percentile of |Zm(s2)| iterates taken from S(s1).
The calculation of CVs in the general case with an arbitrary spending function α(γ) is
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similar. At analysis time sk with γk, estimate Σk and generate M mean zero multivariate nor-
mal iterates, {Zm(s1), . . . , Zm(sk)}, with correlation (covariance) matrix Σk,m = 1, . . . ,M .
Calculate the subset of iterates S(sk−1) that fail to reject the null hypothesis at all previous
interim analyses 1, . . . , k−1. Then cU(sk) is the 1− α(γk)−α(γk−1)1−α(γk−1) percentile of |Zm(sk)| iterates
taken from the set S(sk), and cL(sk) = −cU(sk).
4.2 Asymmetric Type I Error Control and Patient Protection
Symmetric stopping boundaries make it equally difficult to reject the null hypothesis due to
treatment benefit or harm. These bounds are appropriate when trial monitors are blinded
to the identity of the superior treatment arm at each analysis. Modern Data and Safety
Monitoring Committees are rarely blinded, however, and in cases where the control is a viable
therapeutic choice, there is additional motivation to end a trial where the investigational arm
is trending towards harm. For the remainder of this section we consider asymmetric stopping
boundaries, classified as efficacy, safety or futility bounds.
The priority of the efficacy stopping bound is to limit the clinical trial false positive rate
to α/2, where a false positive clinical trial is defined as a trial that incorrectly stops in favor
of the investigational arm. Typically we choose α/2 = 2.5% and use a traditional spending
function approach for this bound. This bound is tightly linked to overall study power. When
triggered, futility and safety bounds stop the trial without favoring the investigational arm,
but are motivated by different desired operating characteristics of the trial.
The goal of a futility boundary is to terminate the trial once it seems unlikely to end
with statistical evidence favoring the investigational arm (Ware et al., 1985). Criteria for
defining a futility boundary are variable, chosen to have simulated operating characteristics
attractive to the trial sponsor and investigative team in the trial’s design phase. Such
boundaries are much more aggressive at ending an unpromising trial than when compared to
a symmetric stopping rule; trial sponsors using a futility boundary avoid spending resources
that prove their latest offering is significantly worse than the current standard of care.
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Although this logic suggests a cost-benefit motivation, such boundaries have the added
attraction of stopping a trial before even weak statistical evidence of harm attributed to
the clinical trial has been obtained. Further discussion of futility stopping boundaries with
examples can be found in Friedman et al. (2015); Harrington (2012). If the only goal of a
clinical trial is to move forward with a new therapeutic, the financial and ethical protection
afforded by futility boundaries are quite attractive.
The distinction we place between a safety boundary and a futility boundary is that safety
boundaries never recommend ending a trial early if the investigational arm is performing at
the level of or superior to the control arm. Symmetric OF and Pocock stopping rules include
a boundary that can be classified as a safety boundary, the boundary that ends the trial
in favor of the control when crossed. Hereafter, we refer to these as OF or Pocock safety
boundaries. It is possible to mix and match efficacy and safety boundaries using commercial
software, for instance an OF efficacy boundary may be paired with a Pocock safety boundary
(Proschan et al., 2006). Traditional type I error is maintained at level α, with α/2 type I
error generated from efficacy and safety boundaries, respectively. The OF efficacy bound
encourages additional follow-up time for collecting data on secondary endpoints when the
investigative arm is favored, while the Pocock safety boundary allows for an earlier average
stopping time when the treatment arm reflecting current medical practice is favored.
In updating our own thoughts on safety boundaries, we note that (1) in the era of big
data (proteomics, genetics. microbiome, etc.), clinical trial auxiliary data is tremendously
valuable. Clean prospective longitudinal follow-up can generate preliminary data on disease
mechanism, therapeutics and personalized medicine, for a start. For this reason, futility
boundaries with very early termination of unpromising therapies seem less appealing. How-
ever, (2) we feel uncomfortable with current OF and Pocock safety boundaries that require
statistically significant harm attributed to the investigational therapy before stopping a trial.
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For our own clinical trials, we have sought solutions via asymmetric boundaries inspired
by Jennison and Turnbull with ideas incorporated from Proschan et al. as well as DeMets
and Lan (Jennison and Turnbull, 2000; Proschan et al., 2006; DeMets and Lan, 1994). In
particular, we recommend a safety bound modified from a Jennison and Turnbull (JT)
spending function, αJT (γ) = γ
ωαsafety, where γ is the proportion of information at the interim
analysis, ω > 0 is a user-defined shape parameter and αsafety > 0 is a user-specified overall
error rate for exceeding the safety boundary and stopping the trial under the null hypothesis.
Our recommendation for ω is log
{
α−1safetyα/2
}
/log(γ), which allows the trial to terminate at
the first interim analysis time if the test statistic indicates harm from the investigational
therapy at the α/2 significance level; hereafter we call this the JT safety boundary.
Figure 2 displays symmetric, futility and safety boundaries for a trial planning 5 interim
analyses using a standardized test statistic; an OF efficacy bound with a 2.5% false positive
clinical trial rate is also shown. OF and Pocock safety boundaries are also shown, where the
overall probability of ending the trial incorrectly due to safety is taken to be 2.5% for each of
these boundaries. The displayed JT safety boundary assumes αsafety = 0.20 and α/2 = 0.025,
so that ω ≈ 1.29. The displayed Pampallona and Tsiatis (PT) futility bound (Pampallona
and Tsiatis (1994)) is the only bound with potential to stop the trial while the investigational
arm is performing at or above the level of the control.
[Figure 2 about here.]
5. Simulation Study
In this section we summarize finite sample operating characteristics of our test statistic, with
τ = 1 year, against the most popular group sequentially monitored tests: the logrank test and
the restricted mean survival test (RMS). In Web Appendix D of supplementary materials we
summarize results for our test statistic using alternative choices of τ = 0.25, 0.50 and 0.75
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years as well as results for weighted logrank tests that use Peto & Peto’s weight favoring early
treatment differences and Fleming and Harrington’s (0.5, 0.5) weight favoring late differences.
In each setting we use an OF efficacy bound with a 2.5% false positive clinical trial rate.
For safety, we consider (1) an OF safety boundary and (2) a Pocock safety boundary, where
each of these assume an overall 2.5% chance of ending the trial incorrectly due to safety.
And finally, we consider (3) a JT safety boundary assuming αsafety = 0.20 and α/2 = 0.025.
Each scenario assumes a 5 year study with 100 participants per treatment arm; 50 partic-
ipants per group are accrued at baseline with the remainder accrued uniformly over 4 years.
Interim analysis are conducted annually (K = 5). In addition to administrative censoring at
each analysis time, we assume a loss-to-follow-up mechanism, Vi = 5Bi+E˜i×(1−Bi), where
Bi and E˜i are distributed as Bernoulli(0.3) and Exponential with hazard 0.3, respectively.
Event times are generated from exponential or piecewise exponential distributions. In
Scenario 1, both intervention and control arms have hazards of 0.5 throughout follow-up (null
hypothesis scenario). Scenarios 2-9, shown in Figure 3 with piecewise hazards superimposed
over the various survival curves, consider proportional hazard alternatives (Scenarios 2-
3), delayed treatment effect alternatives (Scenarios 4-5), early treatment differences that
attenuate over time (Scenarios 6-7) and alternatives subject to a cure pattern (Scenarios 8-
9). Left and right panels of Figure 3 show scenarios where the investigational arm is beneficial
or harmful, respectively; asymmetric stopping rules have different operating characteristics
depending on the benefit/harm profile of the investigational arm.
[Figure 3 about here.]
Tables 1 and 2 summarize group sequential operating characterics in Scenarios 1 though 9.
Table 1 shows rates of stopping for perceived efficacy (column 3) or a perceived safety signal
(columns 4-6). Table 2 shows the average study time (AST), the average sample number
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(ASN) and the average number of events (ANE) for each scenario. For improved precision,
scenario 1 includes 10,000 iterations; scenarios 2-9 include 1,000 iterations.
[Table 1 about here.]
[Table 2 about here.]
Table 1, Scenario 1, shows that under the null hypothesis, all of the estimated efficacy
and safety stopping rates meet their corresponding design targets within our tolerance for
simulation error, where these targets were 0.025 for the OF Efficacy boundary, 0.20 for the
JT safety boundary and 0.025 for the OF and Pocock safety boundaries. The JT safety
boundary ends the trial more frequently (Table 1) and earlier (AST in Table 2) than either
the Pocock or OF safety boundaries in Scenario 1. Regardless of the test statistic used, the
JT safety boundary tends to end the trial 0.3-0.4 years earlier with 5 fewer patients enrolled
and 7-9 fewer events observed (See AST, ASN and ANE, respectively in 2).
Regardless of test statistic used, in scenarios where the investigational drug is harmful
(Scenarios 3, 5, 7, and 9), the JT safety boundary reaches a safety signal at a much higher
rate than its competitor safety bounds (Table 1) and with a much smaller AST, ASN and
ANE (Table 2). In scenarios where the investigational drug is beneficial (scenarios 2, 4, 6
and 8), the additional safety conferred by use of the JT bound does not reduce study power
except very modestly in scenario 4, where the treatment benefit does not emerge until after
the first interim analysis. In this one case, less than a percentage point of simulated power
is lost when using the JT safety boundary compared to the other safety boundaries.
For proportional hazards scenarios (Table 1, Scenarios 2-3), all three test statistics have
comparable probabilities of stopping for efficacy (Scenario 2) or safety (Scenario 3), with
the logrank test edging out its competitors very slightly. Table 2, likewise, gives very similar
AST, ASN and ANE results for the three test statistics.
In Scenarios 4-5, where there is a delayed treatment effect, the proposed statistic has at
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least 10% higher power (Scenario 4, Table 1) with a better safety profile (Scenario 5, Table
1) compared with both the logrank and RMS tests. Modest improvements in AST, ASN and
ANE are also attributed to use of the proposed test statistic (Scenarios 4-5, Table 2).
In Scenarios 6-7, where an early treatment difference emerges but becomes attenuated
over time, power increases by approximately 2 percentages points when moving from the
proposed to the logrank test, and from the logrank to the RMS test (Scenario 6, Table 1).
Safety profiles, AST, ASN and ANE likewise slightly favor the RMS procedure over the
logrank and proposed test, respectively (Scenario 7, Tables 1 and 2).
In Scenarios 8-9, where a cure pattern emerges during the trial, the proposed test statistic
has approximately 2% and 10% higher power than the logrank and RMS tests, respectively
(Scenario 8, Table 1). Safety profiles shown for Scenario 9 in Table 1 likewise reflect a slight
improvement over the logrank test and a large improvement over the RMS test. AST, ASN
and ANE results, however, show only minimal differences (Scenario 8-9, Table 2).
6. Example
Fischl et al. (1990), on behalf of the AIDS Clinical Trials Group (ACTG), randomized
524 patients to high-dose (n=262) versus low-dose (n=262) azidothymidine (AZT). The
standard, higher AZT dose succeeded in reducing mortality but came with substantial
toxicity. Investigators hoped that the lower dose would reduce toxicity while maintaining the
survival benefit. Figure 4(a) displays the average number of additional days lived per year
when taking low versus high dose AZT, estimated using our methodology with τ = 1 year,
at analysis times in 1987, 1988, 1989 and 1990. Although validity of our testing procedure
does not require a stable treatment effect over time, the low-dose AZT benefit appears
approximately stable at each analysis. Using our proposed group sequentially monitored
test statistic, the OF efficacy boundary is crossed at the 1990 analysis with the low dose
group living an estimated 10.7 days longer per year than the high dose group. The JT safety
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boundary ensures early trial termination if the experimental low-dose trends towards higher
mortality, but this boundary was not crossed. Web Appendix E of supplementary materials
summarizes how group sequentially monitored logrank and RMS tests performed in this
case. As seen in Figure 4(b), there was a delayed treatment effect that perhaps favored our
methodology as compared to the logrank and RMS methods. Neither of these competitors
recommended stopping at the 1990 analysis time.
[Figure 4 about here.]
7. Discussion
There are a good many nonparametric group sequential monitoring methods available for
censored time-to-event outcomes in clinical trials, the logrank test and the RMS test among
the most popular, and so a natural question is what the proposed test statistic offers clinical
trial researchers that the others do not. We see both philosophical and operational advantages
to this statistic being used in practice. The philosophical argument hinges on the idea that
times-to-event can be repurposed into a longitudinal data structure, with repeated measures
within individual measured regularly throughout follow-up. Each τ -restricted time-to-event
carved from the overall follow-up time can be thought of as a longitudinal measure in this
philosophy. Tayob and Murray (2016) proposed an improved estimate of τ -restricted means
based on this idea and showed that τ -length follow-up windows starting every τ/2 time units
apart give attractive efficiency in estimating restricted means without unduly increasing
computational time in creating these longitudinal measures. They extended this idea to the
parametric setting in Tayob and Murray (2017), multiply imputing censored event times and
then using standard generalized estimating equation methods for analyzing the longitudinal
restricted event times. There is great potential in shifting our thoughts on censored times-to-
event towards longitudinal data structures and the available methodology this shift entails.
In this manuscript, we develop a two-sample test statistic based on comparing τ -restricted
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means as introduced in Tayob and Murray and we further develop group sequential mon-
itoring methodology for using the test statistic in standard clinical trial settings where
interim monitoring is common. The validity of the proposed testing procedure does not hinge
upon stability of τ -restricted means in the different follow-up windows; the type I error is
preserved regardless of the true event-time distribution. In scenarios where τ -restricted means
are not stable over time, the test statistic compares overall τ -restricted means of mixture
distributions that result from combining information from overlapping follow-up windows.
Event rates that shift year-by-year affect the power of all two sample testing procedures. It
is well known that non-proportional hazards plague the power of the logrank test. Restricted
mean differences also change as the period of follow-up lengthens, with differences becoming
larger or smaller as event rates shift over time. As with all two-sample tests, as data
accumulates, so does our interpretation of the data and the power of the testing procedure.
The main concern in choosing any two-sample test statistic is whether authentic treatment
differences can be detected with high power.
Our proposed method performs well not only in scenarios where short-term differences are
anticipated to be stable, but also in settings that it may be hard to anticipate in the design
stage of a clinical trial. We find it comforting that our methodology compares favorably to
its competitors in proportional hazards settings, and has a notably improved performance in
settings where treatment differences emerge only after a certain period of time or in settings
where there is potential for cure.
Simulations suggest that shifting towards a longitudinal view of censored survival outcomes
has practical advantages in group sequential monitoring of clinical trials. The feature of
overlapping follow-up windows used in creating repeated τ -restricted event times subject to
censoring is reminiscent of smoothing methods in graphical displays of longitudinal data.
An additional contribution of this manuscript is an updated look at safety boundaries in
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the group sequential setting and a new recommendation for the shape parameter ω used with
the JT spending function. Our recommended shape boundary allows the first interim analysis
to reject if the standardized normal test statistic exceeds the safety boundary of -1.96, which
clinical investigators have been hard-wired to associate with statistical significance. Data
and safety monitoring committees are likely to feel uncomfortable continuing a trial that
exceeds this critical value and yet for many years biostatisticians have taught investigators
the consequences of using traditional significance levels in the group sequential setting in
terms of inflated type I errors. This manuscript emphasizes the idea that type I error inflation
has different consequences for the efficacy boundary as opposed to the safety boundary.
We argue that is is possible to maintain an overall false positive trial result to an α/2
level using an appropriate efficacy boundary and separately strategize a stopping rule that
protects safety without unduly reducing power of the study. Our recommended variant of
the JT safety bound achieves this goal with remarkable effectiveness as seen in simulation.
We ultimately recommend use of our proposed test statistic in the group sequential setting
using OF efficacy and our JT safety boundaries.
8. Supplementary Materials
Web Appendices A-E are available at the Biometrics website on Wiley Online Library. An R
package implementing the proposed test is available at https://github.com/summerx0821/
Nonparametric-GS-Methods-for-Evaluating-Survival-Benefit as well as the Biomet-
rics website on Wiley Online Library.
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Figure 1. Notation for 3 example individuals, with random variables specific to Subject
A given in detail (This figure appears in color in the electronic version of this article.)
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Figure 2. Example of Efficacy, Futility and Safety Boundaries
(OF: O’Brien and Fleming; PT: Pampallona and Tsiatis; JT: Jennison and Turnbull)
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Table 1
Rates of stopping for efficacy (OF Efficacy) or for safety (JT Safety, P Safety, OF Safety)
Scenario Test Statistic OF Efficacy JT Safety P Safety OF Safety
Proposed 0.022 0.198 0.026 0.025
1 RMS 0.023 0.198 0.027 0.027
Logrank 0.022 0.193 0.022 0.024
Proposed 0.807 0.002 0 0
2 RMS 0.816 0.001 0 0
Logrank 0.820 0.001 0 0
Proposed 0 0.982 0.790 0.838
3 RMS 0 0.980 0.786 0.852
Logrank 0 0.987 0.799 0.849
Proposed 0.855-0.863 † 0.021 0.007 0.001
4 RMS 0.715-0.722 † 0.034 0.010 0
Logrank 0.745-0.749 † 0.026 0.007 0
Proposed 0 0.979 0.787 0.860
5 RMS 0 0.939 0.619 0.731
Logrank 0 0.959 0.642 0.765
Proposed 0.761 0 0 0
6 RMS 0.802 0 0 0
Logrank 0.781 0 0 0
Proposed 0 0.960 0.709 0.738
7 RMS 0 0.965 0.736 0.786
Logrank 0 0.971 0.730 0.764
Proposed 0.884 0 0 0
8 RMS 0.771 0.001 0 0
Logrank 0.863 0 0 0
Proposed 0 0.989 0.847 0.885
9 RMS 0 0.955 0.727 0.770
Logrank 0 0.983 0.826 0.871
† There is potential for OF efficacy rates to be affected by the safety boundary used, for instance when an
efficacy boundary would have been crossed if not for an earlier safety boundary being crossed. This was only
observed in Scenario 4 of our simulations. In this scenario we give a range of observed OF efficacy stopping
rates for each test statistic, where the lower OF efficacy stopping rate shown corresponds to use of the JT
safety boundary (most strict safety boundary) and the higher OF efficacy stopping rate shown corresponds
to the OF safety boundary (least strict safety boundary).
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Table 2
Average study time (AST) in years, average sample number (ASN) and average number of events (ANE) in
Scenarios 1 - 9
AST ASN ANE
Scenario Test Statistic JT P OF JT P OF JT P OF
Proposed 4.7 4.9 5.0 195 199 200 156 163 164
1 RMS 4.6 4.9 5.0 195 199 200 156 163 164
Logrank 4.7 4.9 5.0 195 199 200 156 164 165
Proposed 3.7 3.7 3.7 185 185 185 143 143 143
2 RMS 3.7 3.7 3.7 184 184 184 142 142 142
Logrank 3.7 3.7 3.7 185 185 185 143 143 143
Proposed 2.1 3.0 3.6 151 169 184 93 121 142
3 RMS 2.1 3.1 3.6 151 170 183 93 123 141
Logrank 2.0 3.0 3.6 149 169 184 90 121 141
Proposed 3.7 3.8 3.8 187 188 188 132 134 134
4 RMS 4.2 4.3 4.3 193 195 196 143 146 147
Logrank 4.0 4.1 4.1 191 192 193 140 142 143
Proposed 2.8 3.8 3.9 169 185 189 108 132 137
5 RMS 3.4 4.3 4.3 180 193 195 123 146 147
Logrank 3.0 4.1 4.2 173 189 193 113 140 144
Proposed 3.7 3.7 3.7 184 184 184 143 143 143
6 RMS 3.6 3.6 3.6 183 183 183 141 141 141
Logrank 3.7 3.7 3.7 184 184 184 143 143 143
Proposed 2.2 3.2 3.8 153 171 185 96 126 145
7 RMS 2.2 3.2 3.6 153 171 183 96 126 142
Logrank 2.1 3.1 3.7 150 170 184 92 124 143
Proposed 3.4 3.4 3.4 181 181 181 128 128 128
8 RMS 3.7 3.7 3.7 183 183 183 132 132 132
Logrank 3.5 3.5 3.5 182 182 182 130 130 130
Proposed 2.1 3.0 3.5 152 169 182 92 113 130
9 RMS 2.2 3.2 3.7 154 172 184 94 118 133
Logrank 2.0 3.0 3.6 150 169 183 90 113 131
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